Comparative effectiveness of mirikizumab and risankizumab in patients with ulcerative colitis: A propensity-matched cohort study
{{output}}
Background and objectives: Mirikizumab and risankizumab are both anti-IL23 therapies approved for moderate-to-severe ulcerative colitis (UC); however, there is no comparative data to guide their clinical use. ... ...
